The complex biochemical effects of RAF inhibitors account for both the effectiveness and mechanisms of resistance to these drugs, but a unified mechanistic model has been lacking. Here
INTRODUCTION
The RAS-RAF-MEK-ERK signaling pathway (ERK signaling) is a major regulator of mammalian cell proliferation and survival (Matallanas et al., 2011; Roberts and Der, 2007; Young et al., 2009) . Growth factor receptor activation promotes transition of RAS to its active, GTP-bound state. Activation of the three RAF isoforms (ARAF, BRAF and CRAF) is induced by their binding via their RAS-binding domain to RAS-GTP at the membrane, which results in activating phosphorylation of CRAF at S338 and perhaps additional residues, as well as RAF homodimerization or heterodimerization (Weber et al., 2001; Wellbrock et al., 2004) . Activated RAF initiates a three-tier kinase cascade by phosphorylating and activating MEK, which in turn phosphorylates and activates ERK.
ERK signaling has been found deregulated in a large portion of cancers, most commonly by mutations in the RAS gene family or in BRAF (Roberts and Der, 2007) . The most common BRAF mutation (BRAF V600E ), found in about 8% of human tumors and more than 50% of melanomas, results in ERK signaling upregulation, independent of RAS activity (Davies et al., 2002; Wan et al., 2004) . The FDA-approved RAF inhibitors vemurafenib and dabrafenib have elicited responses and extended survival of patients with BRAF V600E melanomas (Chapman et al., 2011; Falchook et al., 2012; Flaherty et al., 2010; Hauschild et al., 2012) . However, responses are almost universally followed by the development of clinical resistance, indicating the need for improved therapies.
The current clinical RAF inhibitors suppress RAF activity selectively in cells expressing BRAF V600E (Halaban et al., 2010; Hatzivassiliou et al., 2010; Heidorn et al., 2010; Joseph et al., 2010; Poulikakos et al., 2010) , and they do not inhibit wild-type BRAF because it signals as dimer Yao et al., 2015) . This is the basis of the high therapeutic index of these drugs, but RAF dimerization is also predicted to result in drug resistance Samatar and Poulikakos, 2014) . Indeed, mechanisms that result in increased RAF dimerization, such as upregulation of receptor tyrosine kinases (RTK) signaling, RAS mutation, BRAF amplification and expression of splice variants of BRAF V600E were reported to be responsible for clinical resistance to RAF inhibitors (Corcoran et al., 2011; Nazarian et al., 2010; Poulikakos et al., 2011; Shi et al., 2012; Villanueva et al., 2010) .
2012; Yao et al., 2015) . Furthermore, preclinical and clinical evidence suggests that these RAF inhibitors will not be effective in colorectal and thyroid BRAF V600E tumors due to relief of negative feedback and RTK-mediated reactivation of ERK signaling (Corcoran et al., 2012; Montero-Conde et al., 2013; Prahallad et al., 2012) . Thus, there is pressing need for the development of more effective inhibitor-based therapeutic strategies to target BRAF oncogenic signaling in various clinical contexts.
The current clinical RAF inhibitors have unique biochemical properties. They bind and inhibit all RAF isoforms in in vitro kinase assays, but they suppress RAF activity and downstream ERK signaling selectively in cells expressing BRAF V600E (Halaban et al., 2010; Hatzivassiliou et al., 2010; Heidorn et al., 2010; Joseph et al., 2010; Poulikakos et al., 2010) . In cells with BRAF WT they paradoxically activate RAF and ERK signaling, via a RASdependent mechanism that remains incompletely understood. Recently, a number of RAF inhibitors with diverse structural and biochemical properties entered preclinical and clinical development Peng et al., 2015; Zhang et al., 2015) . We sought to develop an integrated model of RAF inhibitor action that would explain the biochemical effects of RAF inhibitors based on their structural properties in any cellular context.
RESULTS

Structurally diverse RAF inhibitors equi-potently inhibit monomeric and dimeric RAF
To identify potent inhibitors of dimeric BRAF, we compared eight structurally diverse RAF inhibitors: AZ-628 (AZ) (McDermott et al., 2007) , TAK-632 (TAK) , LY3009120 (LY) (Peng et al., 2015) , GDC-0879 (GDC) (Hoeflich et al., 2009) , SB-590885 (SB) (King et al., 2006) , PLX7904/Paradox Breaker (PB), which does not to induce paradoxical activation in wild-type BRAF cells , Vemurafenib (VEM) and Dabrafenib (DAB) (Rheault et al., 2013) (Figure S1A , Table S1 ). To compare potencies of inhibitors in cells endogenously expressing monomeric or dimeric BRAF V600E , we treated parental (PAR) SKMEL239 cells expressing full length BRAF V600E and the SKMEL239 derivative (clone C3) that is resistant to VEM due to enhanced dimerization of endogenous splice variants of BRAF V600E that lack the RAS-binding domain (Poulikakos et al., 2011) . For each RAF inhibitor, we determined the IC 50 for ERK signaling and cell growth in either PAR or C3. We found that AZ, TAK, LY, GDC and SB inhibit monomeric and dimeric BRAF V600E with similar potency (less than 10-fold difference between the IC 50 s of PAR and C3 for both ERK signaling inhibition and in cell growth assays), whereas PB, DAB and VEM showed potent inhibition of monomeric BRAF V600E but 30 to 100-fold less potency for inhibition of dimeric BRAF V600E ( Figure  1A -C and Figure S1B ). Similar results were obtained in two additional vemurafenibresistant BRAF V600E melanoma cell lines, due to either expression of mutant NRAS (M249) (Nazarian et al., 2010) or expression of a different BRAF V600E splice variant than SKMEL239-C3 cells (M397) (Shi et al., 2012) (Figure 1D , E and S1C, D)
The structural basis of RAF inhibitor resistance due to RAF dimerization is negative allostery for inhibitor binding to the second protomer due to the OUT position of the αC-helix To identify the structural basis of resistance of dimeric RAF to RAF inhibitors, we examined crystal structures of BRAF bound to inhibitors. In the BRAF/TAK structure, TAK stabilizes the αC-helix towards the IN (active) position, which allows binding of a second TAK molecule to the second protomer ( Figure 1F ). In contrast, in the reported BRAF-VEM structure, one protomer of the BRAF dimer is occupied by VEM and the other is unoccupied . We noticed that the stabilization of the αC-helix towards the OUT (inactive) position promoted upon binding of VEM to one protomer does not allow the same movement of the αC-helix in the other protomer, because the αC-helix of the second protomer cannot move towards the OUT position without breaking the RAF dimer ( Figure  1F, insert) . Thus, the position of the αC-helix stabilized in the drug-bound protomer results in reduced affinity of the drug for the second protomer due to a steric hindrance mechanism.
To further investigate the interplay between drug occupancy and BRAF dimerization, we generated crystal structures, after introducing the R509H mutation (Rajakulendran et al., 2009) in the dimer interface of the catalytic domain of BRAF bound to VEM and AZ, respectively (Table S2) . VEM bound to BRAF R509H stabilizes BRAF in a monomeric and inactive state (Figure S1E, S1F) with the αC-helix in a further OUT position compared to the αC-helix position in the dimeric BRAF bound to VEM ) ( Figure  S1G -I) precluding the stabilization of the BRAF dimer, similarly to another monomeric BRAF structure bound to a different sulfonamide inhibitor (Thevakumaran et al., 2015) . Thus, introduction of the R509H mutation in the dimer interface allows the disruption of the BRAF dimer by VEM, in vitro. In contrast, AZ stabilizes the αC-helix of BRAF R509H towards the IN position, allowing the formation of a dimeric BRAF structure with AZ bound to both protomers, despite the R509H mutation ( Figures S1I, S1J ). These data indicate that when in cells BRAF molecules with intact dimer interface form stable dimers, RAF inhibitors that stabilize the αC-helix towards the OUT position (αC-OUT inhibitors) are sterically prevented from occupying both protomers. In contrast, inhibitors that stabilize the αC-helix towards the IN position (αC-IN inhibitors) are structurally more compatible with the dimeric form of RAF and will be thus more effective inhibitors of dimeric RAF.
It has been proposed that protomer occupancy by inhibitor is determined by the DFG-OUT position stabilized by certain RAF inhibitors, such as LY and TAK (Peng et al., 2015) . However, we found that both αC-helix-IN/DFG-OUT (TAK, LY, AZ) and αC-helix-IN/ DFG-IN inhibitors (GDC and SB) show similar potency in inhibiting monomeric and dimeric RAF ( Figure 1A-C) . We thus conclude that the position of the αC-helix stabilized by inhibitor determines protomer occupancy.
The extent of negative allostery for inhibitor binding to the second protomer can be illustrated by the difference in the position of the αC-helix after superimposing the two protomers based on the crystal structure of dimeric BRAF bound to each inhibitor ( Figure  1G ). αC-IN inhibitors stabilize both RAF protomers with the position of αC-helix in a similar conformation (towards the IN position) and thus, both protomers can be occupied by inhibitor at lower concentrations. In contrast, the protomers bound to αC-OUT inhibitors have the position of αC-helix in different conformations (towards the OUT or the IN position), indicating high allosteric hindrance for inhibitor binding to the second protomer ( Figure 1G ).
A chimeric compound derived from an αC-IN inhibitor that stabilizes the αC-helix in the OUT position is an inefficient inhibitor of dimeric RAF The core structures of VEM and AZ bind to BRAF in a very similar location within the binding site whereas their "head" groups interact differently with the αC-helix and DFG motif ( Figure S1F ). VEM uses a substituted sulphonamide group that extends inside the catalytic pocket stabilizing the αC-helix closer to the OUT position, whereas AZ has a bulkier substituted acetamide group that extends outside the catalytic pocket stabilizing the αC-helix closer to the IN position. To directly assess whether the position of the αC-helix determines inhibitor activity against dimeric RAF, we synthesized a chimeric compound (AZ-VEM) that includes an AZ-like core structure attached to the same substituted sulphonamide group from VEM ( Figure 2A ) and determined the crystal structure of BRAF bound to AZ-VEM at a 1.95Å resolution. Consistent with our hypothesis, AZ-VEM bound to the first protomer of BRAF stabilized the αC-helix towards an OUT position, similar to the BRAF/VEM structure ( Figure 2B ). Similar to αC-OUT inhibitors, overlay of the two protomers of the BRAF/AZ-VEM structure revealed negative allostery for inhibitor binding to the second protomer ( Figure 2C ). Finally, as expected, AZ, AZ-VEM and VEM potently inhibited ERK signaling and cell growth in VEM-sensitive Parental cells but AZ-VEM was ineffective in inhibiting both ERK signaling and cell growth in VEM-resistant cells ( Figure  2D , E and S2A-C). Thus, the position of the αC-helix determines inhibitor activity against dimeric RAF and suggests a rational design strategy for tuning RAF inhibitor selectivity against dimeric BRAF.
RAF dimerization promoted by αC-IN inhibitors in cells is a consequence of the formation of the active RAF/RAS-GTP complex
RAF inhibitors suppress monomeric BRAF V600E , but they have been shown to induce RAF priming (CRAF S338 phosphorylation) and BRAF/CRAF dimerization and activation of downstream ERK signaling in BRAF WT -expressing cells. It is however not understood how an inhibitor can both promote RAF dimerization and fail to inhibit the formed RAF dimers. To gain mechanistic insights, we first treated SKMEL2 (BRAF WT NRAS Q61R ) cells with RAF inhibitors and found that αC-IN inhibitors strongly promoted RAF priming and BRAF/ CRAF dimerization. In contrast, VEM showed modest induction of p-CRAF S338 and BRAF/ CRAF dimerization and PB did not induce p-CRAF S338 or BRAF/CRAF dimerization ( Figure 3A , B). To directly compare the induction of the activated state of RAF between αC-IN and αC-OUT inhibitors, we performed in vitro kinase assays of immunoprecipitated V5-tagged CRAF from HCT116 (KRAS G13D ) cells after pretreatment with RAF inhibitor followed by wash out of the compound. Pretreatment of cells with SB or GDC resulted in much higher induction of the in vitro kinase activity of CRAF compared to VEM and PB ( Figure 3B ).
Inhibitors that stabilize a closed RAF kinase domain conformation promote RAF dimerization of purified RAF catalytic domains (Lavoie et al., 2013; Thevakumaran et al., 2015) . However, inhibitor-induced RAF dimerization in cells requires the presence of RAS-GTP (Hatzivassiliou et al., 2010; Heidorn et al., 2010; Lavoie et al., 2013; Poulikakos et al., 2010) . To understand the requirement of RAS-GTP in RAF priming by inhibitors, we established a chemical-induced dimerization (CID) system by ectopic expression of either CRAF engineered to dimerize (CRAF-dim) or both CRAF and BRAF engineered to dimerize (CRAF-dim and BRAF-dim) upon addition of AP20187 (AP) ( Figure S3A ). We next compared CID RAF dimerization to treatment with RAF inhibitors. Addition of AP in cells ectopically expressing CRAF-dim resulted in increased CRAF kinase activity and induction of ERK signaling (Figures 3C and S3B) . Similarly, treatment with AP of cells ectopically co-expressing BRAF-dim and CRAF-dim resulted in induction of BRAF/CRAF dimerization and activation of ERK signaling ( Figure S3C ). However, in contrast to treatment with RAF inhibitor, in neither case did we observe an increase in CRAF S338 phosphorylation ( Figures 3C, S3C ).
To investigate in more detail the requirement of RAS-GTP for the effects of RAF inhibitors, we established a cell line model with tunable RAS-GTP, similar to our previous report (Yao et al., 2015) . In PC9 cells, RAS-GTP levels are under the control of mutant EGFR. Treatment of PC9 cells with the EGFR inhibitor gefinitib (GEF) suppressed EGFR activity and downstream signaling ( Figure S3D ) and inhibited RAS-GTP and BRAF/CRAF dimerization to levels similar to those in the BRAF V600E -expressing A375 cells (Figures S3E, S3F) . First, to exclude the possibility of induction of RAS-GTP levels by RAF inhibitors which would in turn result in RAF priming, we treated PC9 cells with AZ or TAK and found that p-CRAF S338 induction is not associated with any increase in RAS-GTP levels ( Figure 3D ). Thus, our data indicate that inhibitor-induced RAF dimerization is the consequence of the interaction of RAF with RAS-GTP and CRAF S338 phosphorylation. Consistent with this model, in SKMEL2 cells, the αC-IN inhibitor AZ, but not the αC-OUT inhibitor PB, promoted RAF binding to endogenous RAS ( Figure 3E ). Furthermore, in PC9 cells, treatment with αC-IN inhibitor AZ, but not with the αC-OUT inhibitor PB, resulted in formation of the CRAF/BRAF/RAS complex, an effect that was abolished after pretreatment with GEF ( Figure S3G ). Finally, ectopic expression of mutant KRAS G12V in the presence of GEF restored induction of p-CRAF S338 and the formation of the RAF/RAS complex after treatment with AZ ( Figure S3H ).
The position of R506 in the αC-helix of BRAF predicts inhibitor-induced RAF priming and dimerization
Closer examination of the structural data and the biochemical effects of inhibitors indicated that it is a certain area and not the overall position of the αC-helix that determines inhibitorinduced RAF/RAS-GTP interaction. We found that DAB and AZ-VEM, although αC-OUT inhibitors, promote RAF priming and dimerization more potently than VEM and PB and at levels closer to αC-IN inhibitors ( Figures 4A-C) . Structural analysis revealed that the residue R506 of αC-helix adopts a distinct conformation from the binding of each inhibitor. The side-chain conformation of R506 is in a further OUT position in PB and VEM-bound structures, whereas αC-IN inhibitors stabilize R506 closer to IN position. DAB and AZ-VEM stabilize the αC-helix in an overall OUT position, but R506 in a further IN position compared to PB and VEM, and closer to the position stabilized by αC-IN inhibitors ( Figure  4D ). These data suggest that the inhibitor-induced interaction of RAF with RAS-GTP can be predicted by the degree of movement of R506 away from the OUT position.
The effect of RAF inhibitor in cells expressing RAS-GTP is the combined outcome of distinct allosteric mechanisms
Our results indicate that resistance due to RAF dimerization and RAF kinase priming by inhibitors are regulated by distinct allosteric mechanisms. RAF priming is the result of increased RAF binding to RAS-GTP. Resistance to dimeric RAF is the result of allosteric interaction between the catalytic domains of a RAF dimer. The observed effects of RAF inhibitors in cells with high RAS-GTP levels are the combined effects of the two mechanisms. Inhibitor binding to the catalytic domain of RAF promotes RAF binding to RAS-GTP and RAF dimer formation. Newly formed RAF dimers are resistant to inhibition due to negative allostery for inhibitor binding to the second protomer. RAF inhibitors that stabilize R506 in the αC-helix closer to the IN position potently promote RAF priming, while they show minimal negative allostery and inhibit ERK signaling at relatively lower concentrations. RAF inhibitors that stabilize the αC-helix towards the OUT position promote minimal RAF priming, but are less effective in suppressing RAF dimers. In agreement with this model, treatment of SKMEL2 cells with αC-IN inhibitors resulted in ERK signaling activation at lower concentrations and inhibition of ERK signaling below basal levels at 3-10 μM. (Figure 4E ). Two additional RAF inhibitors (CCT196969 and CCT241161) have been reported to have similar biochemical effects on ERK signaling in RAS-mutant cells to the αC-IN inhibitors tested here (Girotti et al., 2015) , but their crystallographic data are currently unavailable. The αC-OUT inhibitors DAB, AZ-VEM and VEM also promote RAF dimer formation, but at lower levels than the αC-IN inhibitors, depending on the extent of displacement of R506 from the OUT position ( Figure 4D ). However, due to higher negative allostery they are less able to inhibit the newly formed RAF dimers. The combined outcome is a strong induction of ERK signaling at moderate and high concentrations of inhibitor in cells with high levels of RAS-GTP ( Figure 4E ). The distinct character of the two allosteric mechanisms is most evident in the case of PB. PB stabilizes both the αC-helix and R506 in the OUT position ( Figure 4D ). This results in near elimination of inhibitor-induced RAF/RAS-GTP complex formation. However, due to negative allostery, PB fails to inhibit the basal levels of wild-type RAF dimers expressed in SKMEL2 cells, already formed downstream of mutant-NRAS. The outcome is the observed, virtually unaffected levels of ERK signaling at any PB concentration.
The conformation stabilized by inhibitor in relation to the active RAF conformation predicts the extent of inhibitor-induced RAF/MEK complex
We observed that the αC-IN/DFG-OUT inhibitors induce relatively lower levels of MEK/ERK phosphorylation than the αC-IN/DFG-IN inhibitors ( Figure 4E ), an observation consistent with the slow off-rate of these compounds (Hatzivassiliou et al., 2010; Nakamura et al., 2013) . Differences in the formation of active signaling complexes have been shown to affect inhibitor potency in cells (Hatzivassiliou et al., 2013) and RAF inhibitor binding has been shown to affect the RAF/MEK interaction (Haling et al., 2014) . We thus compared the formation of the RAF/MEK complex induced by each class of inhibitor. All αC-OUT inhibitors did not promote the formation of the RAF/MEK complex, a result consistent with the promotion of an inactive conformation of RAF. Furthermore, αC-IN/DFG-OUT RAF inhibitors promoted relatively lower levels of RAF/MEK complex than αC-IN/DFG-IN inhibitors ( Figure 4F ). Molecular modeling of the BRAF/MEK complex with BRAF bound to RAF inhibitor revealed that the αC-helix, the DFG motif and the P-loop adopt distinct positions in relation to the active BRAF conformation. The extent of the formation of the RAF/MEK complex for each inhibitor can be predicted by the position of these structural regions compared to active BRAF. Thus, inhibitors that stabilize RAF in a conformation most similar to the active BRAF such as SB (αC-IN/DFG-IN) strongly stabilize the RAF/MEK complex ( Figure S4A-C) . In contrast, inhibitors that induce the αC-OUT or DFG-OUT conformation disfavor the formation of the RAF/MEK complex by destabilizing the RAF dimer interaction or the RAF/MEK interaction within the RAF/MEK tetramer structure (Haling et al., 2014) . Thus, αC-IN/DFG-OUT RAF inhibitors promote less paradoxical MEK/ERK activation than αC-IN/DFG-IN inhibitors due to both slower off-rate and lower induction of the RAF/MEK complex.
Together our data show that the biochemical effect of RAF inhibitors is the combined outcome of distinct allosteric mechanisms ( Figure 4G ).
αC-IN inhibitors show increased activity in BRAF-mutant tumors other than V600
We showed previously that sensitivity of BRAF V600E -expressing tumors to RAF inhibitors requires expression of low levels of RAS-GTP in these cells and is the consequence of the ability of BRAF V600E to signal as a monomer in the absence of RAS-GTP. In contrast to BRAF V600 , introduction of R509H in non-V600 mutant forms of BRAF results in loss of their kinase activity in the absence of RAS-GTP (Yao et al., 2015) . We assessed in more detail the effect of dimerization by ectopically expressing BRAF mutants in PC9 cells. We found that BRAF V600K/D/R mutants retained full activity after introduction of the R509H mutation and were potently inhibited by VEM, similarly to BRAF V600E ( Figure S5A ). Next, we assessed BRAF mutations other than V600 that are found in tumors and the double phospho-mimetic mutant T599E/S602D, whose activity has been shown to be affected by disruption of dimerization (Rajakulendran et al., 2009 ). Activation of ERK signaling was reduced in GEF-treated PC9 cells expressing BRAF K601E and BRAF T599E/S602D and was eliminated in those expressing BRAF G466V and BRAF L597V upon introduction of the R509H mutation. The activity of these BRAF mutants was either partially, K601E and T599E/S602D, or completely, G466V and L597V, resistant to inhibition by VEM and introduction of R509H sensitized both BRAF K601E/R509H and BRAF T599E/S602D/R509H to VEM ( Figure S5B ). Thus, mutations in BRAF that result in BRAF activity dependent either partially (K601E, T599E/S602D) or entirely (G466V, L597V) on dimerization promote resistance to VEM.
We next compared VEM (αC-OUT) to TAK (αC-IN) in non-V600 mutant BRAF proteins expressed in PC9 cells and in the absence of RAS-GTP (GEF-treated). VEM and TAK inhibited all BRAF V600 mutants tested with similar potency ( Figure 5A ). In contrast, dimeric BRAF mutants that showed partial (K601E) or complete (p61BRAF V600E , L597V, G466E) resistance to VEM were effectively inhibited by TAK ( Figure 5B ). We further assessed our panel of RAF inhibitors in cells expressing endogenous non-V600 mutant BRAF. Consistent with above results, in BRAF V600D and BRAF V600R -expressing cells, αC-OUT and αC-IN RAF inhibitors inhibited ERK signaling and cell growth similarly to BRAF V600E -expressing cells ( Figures 5C, 5D and Figures S5C, D) . In contrast, in cancer cell lines expressing mutant forms of BRAF that promote RAF dimerization, αC-OUT inhibitors were significantly less effective than αC-IN inhibitors ( Figures 5E-H and Figures  S5E-H) . Thus, αC-IN inhibitors are more effective inhibitors of endogenously expressed dimeric mutant-BRAF, compared to αC-OUT inhibitors.
αC-IN inhibitors show increased activity in colorectal and thyroid BRAF V600E tumor cells
Colorectal and thyroid BRAF V600E tumors are resistant to first generation RAF inhibitors (Corcoran et al., 2012; Montero-Conde et al., 2013; Prahallad et al., 2012) . To assess whether RAF dimerization contributes to drug resistance in these tumors, we first compared the levels of BRAF/CRAF dimerization between melanoma and colorectal or thyroid BRAF V600E cells lines. BRAF/CRAF dimers were increased in colorectal and thyroid compared to melanoma cells both at baseline and after RAF inhibitor treatment, indicating that these tumor cells are resistant to αC-OUT RAF inhibitors due to increased RAF dimerization ( Figure 6A , B).
We next compared feedback-mediated reactivation of ERK signaling after treatment with either VEM or the αC-IN inhibitor TAK for 48 hours in melanoma and colorectal cells. In BRAF V600E melanoma cells, the same concentration of either VEM or TAK durably suppressed ERK signaling ( Figure 6C ). In contrast, in colorectal cells treatment with VEM resulted in recovery of ERK signaling whereas the same concentration of TAK durably suppressed ERK signaling ( Figure 6D ). Furthermore, VEM suppressed cell growth selectively in BRAF V600E melanoma cells, whereas TAK showed effectiveness in both melanomas and colorectal cells ( Figure 6E and Figures S6A, B) . Similar results were obtained in thyroid tumor cells ( Figure 6F , G and Figure S6C-F) . The data suggest that αC-IN inhibitors may be an effective therapeutic option for patients with colorectal or thyroid BRAF V600E tumors that do not respond to first generation RAF inhibitors.
Therapeutic strategies including αC-IN inhibitors are effective in BRAF V600E models
Normal cells express BRAF WT , which signals as dimer. Thus, αC-IN inhibitors by inhibiting dimeric BRAF WT and downstream signaling also in normal cells may have a lower therapeutic window than αC-OUT inhibitors. We modeled the BRAF WT cell context by using human keratinocytes and the melanoma cell line WM1382 (BRAF WT RAS WT ). In both contexts, we found that αC-IN inhibitors suppressed ERK signaling and cell growth at more than 10-fold lower concentrations than αC-OUT inhibitors ( Figures 7A-C and S7A ). Based on these findings, we assessed strategies including αC-IN inhibitors, either alone, or in combination with VEM.
We first treated two BRAF V600E melanoma cell lines with VEM and resistant clones started developing after about 4 weeks. In contrast, no resistant colonies developed in treatments including TAK ( Figure 7D ). Furthermore, in BRAF V600E colorectal and thyroid cancer cells lines in which VEM was ineffective, all treatments including TAK and LY led to potent suppression of cell growth within 10 days of treatment ( Figure 7E ).
Finally, we assessed treatments with structurally diverse RAF inhibitors in a xenograft BRAF V600E colorectal tumor model. Treatment with the RAF inhibitor PLX4720 (PLX, a close analog to VEM) suppressed ERK signaling in the tumor in 4 hours, but similarly to our cell-based data, we observed recovery of ERK signaling after 24 hours ( Figure 7F ). In contrast, treatment with TAK or the combination TAK/PLX potently and durably suppressed ERK signaling in the tumor ( Figure 7F ). Tumor growth was not suppressed by PLX, however treatment with either TAK or the TAK/PLX combination resulted in potent suppression of tumor growth without an obvious effect on body weight ( Figure 7G and Figure S7B ). Together these data suggest that therapeutic strategies based on αC-IN inhibitors will be more effective in melanoma, colorectal and thyroid BRAF V600E tumors, either alone or included in combinations with currently approved RAF and MEK inhibitors.
DISCUSSION
The complex biochemical effects of RAF inhibitors have been a topic of intensive investigation, but an integrated model of RAF inhibitor action has been lacking. We show here that RAF inhibitors exert their biochemical effects as the combined outcome of distinct allosteric mechanisms. RAF priming and dimerization is the result of inhibitor-induced RAF/RAS-GTP interaction. Resistance to inhibition of dimeric RAF is the result of negative allostery for inhibitor binding to the second protomer due to the OUT position of the αC-helix. Hence, in conditions of elevated RAS-GTP, paradoxical activation of downstream ERK signaling is the result of the equilibrium between RAF dimers that have been formed and failure of inhibitor to inhibit them ( Figure 8A, B) . αC-IN/DFG-OUT inhibitors promote similar levels of RAF priming and dimerization as αC-IN/DFG-IN inhibitors, but induce lower levels of paradoxical activation of ERK signaling, due to decreased formation of the RAF/MEK complex and slower off-rate (Hatzivassiliou et al., 2010; Nakamura et al., 2013) . In cells expressing RAF dimers formed independently of RAS-GTP, the only determining factor of the function of RAF inhibitors is the extent of negative allostery for inhibitor occupancy of both RAF protomers ( Figure 8C ).
Previous studies have shown that αC-OUT inhibitors disrupt the RAF dimer in vitro (Thevakumaran et al., 2015) . Based on our data, αC-OUT inhibitors do not disrupt RAF dimers in cells when used at low and moderate concentrations and the steric inability of the RAF dimer to accommodate simultaneously two αC-OUT inhibitor molecules results in reduced affinity for inhibitor binding to the second protomer.
Promotion of the activated state of RAF by inhibitor has been the subject of a number of previous reports. We and others proposed that RAF activation by inhibitor is a result of allosteric mechanisms (Hatzivassiliou et al., 2010; Poulikakos et al., 2010) , whereas others suggested that the phenomenon is the result of a relief of an inhibitory phosphorylation in RAF, either in cis (Holderfield et al., 2013) or in trans (between BRAF and CRAF) (Heidorn et al., 2010) . Despite the differences in the proposed models, all reports agreed that paradoxical RAF activation by inhibitor requires RAS-GTP. Here we show that inhibitor-induced RAF dimerization is downstream of RAF binding to RAS-GTP as a result of a movement around the R506 residue in the αC-helix of BRAF. This suggests that this area may be critical in the interaction of the catalytic domain with the N-terminus of RAF. Unfortunately, the lack of crystallographic data on RAF encompassing its N-terminus precludes further structural validation of the role of R506, at the moment.
The data presented here have important therapeutic implications. Based on our findings, αC-IN RAF inhibitors are predicted to be more effective than first generation RAF inhibitors for treatment of patients with tumors expressing non-V600 BRAF mutants and in BRAF V600E colorectal and thyroid tumors. They are also predicted to be more effective in patients having tumors with oncogenic deletions in BRAF, as recently reported (Chen et al., 2016; Foster et al., 2016) . However, αC-IN inhibitors may have low therapeutic window, since they will inhibit dimeric BRAF WT also in normal cells. Our data suggest that in the clinic, relatively lower, non-toxic concentrations of αC-IN inhibitors may be effective by including them in combination with currently approved RAF and MEK inhibitor regimens. PB is a potent inhibitor of monomeric BRAF V600E , but is unique because it induces minimal RAF priming and paradoxical ERK signaling activation in BRAF WT -expressing cells. PB is not predicted to induce toxicities related to activation of ERK signaling and may be beneficial in clinical contexts in which chronic treatment may be required, such as adjuvant therapy after resection of primary BRAF V600E melanomas, or treatment of more indolent neoplasias, such as BRAF V600E Langerhans Cells Histiocytosis. However, development of resistance due to RAF dimerization may also limit the effectiveness of PB.
The structural, biochemical and cellular findings reported here enable the rational design of RAF inhibitors with defined biochemical properties and RAF inhibitor-based therapeutic strategies tailored to different cellular contexts.
EXPERIMENTAL PROCEDURES
Compounds and cell lines PLX7904 (Paradox Breaker) was provided by Plexxikon. All other compounds were obtained by Selleckchem. Compounds were dissolved in DMSO to yield 10mM stock. The ligand for chemically induced dimerization AP20187 (Clontech) was dissolved in ethanol. 293H cells were purchased from Life Technologies. WM1341D and WM266 were obtained from the Coriell Cell Repository. SKMEL208 cells were provided by Taha Merghoub and David Solit (MSKCC). Thyroid tumor cell lines 8505C, Hth104 and SW1736 have been authenticated as previously reported (Montero-Conde et al., 2013) . All other cell lines were from ATCC. Cell lines were maintained in DMEM or RPMI supplemented with 10% FBS, 2mM glutamine, and antibiotics (Life technologies). Human epidermal keratinocytes were obtained by Life Technologies and cultured in serum-free EpiLife medium supplemented with 60 μM calcium chloride and human keratinocyte growth supplement.
Animal studies
All mouse experiments were approved by the Icahn School of Medicine at Mount Sinai (ISMMS) Animal Care and Use Committee (protocol no. IACUC-2014-0229) . Mice were maintained under specific pathogen-free conditions, and food and water were provided ad libitum.
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SIGNIFICANCE
The complex biochemical properties of RAF inhibitors have been a topic of intense investigation, but a detailed mechanistic model linking their structural properties to their biochemical effects has been lacking. Recently, a number of RAF inhibitors with diverse structural properties have entered preclinical or clinical development, but the most appropriate clinical context for their use remains elusive. Here we provide an integrated model of RAF inhibitor action as the combined outcome of two distinct allosteric mechanisms. Our model predicts the biochemical effect of any RAF inhibitor based on its structural properties and the cellular context, and provides a blueprint for the development of rationally-designed RAF inhibitors and improved RAF inhibitor-based therapeutic strategies for BRAF-dependent tumors. The blue oval highlights the predicted steric hindrance for binding of a hypothetical VEM molecule in protomer II (insert). (G) Overlay of the two protomers for each BRAF structure bound to inhibitor showing the difference in the position of the αC-helix (red and yellow for each protomer) stabilized by each inhibitor. See also Figure S1 and Tables S1 and S2. (A), Growth factor-induced RAF activation. Under conditions of low RAS-GTP, RAF is cytosolic and inactive (1). Growth factor stimulation upregulates the levels of RAS-GTP, promoting the formation of the RAF/RAS-GTP complex in the membrane, followed by activating CRAF S338 phosphorylation (2) and dimerization for full RAF activation (3). (B), RAF inhibitor-induced RAF activation and allosteric hindrance. RAF inhibitors promote the activated state of RAF by binding to inactive RAF (1) and promoting its interaction with RAS-GTP (2). CRAF bound to RAS-GTP is phosphorylated at S338 and dimerized (3). Inhibitors that bind to one protomer and stabilize the αC-helix closer to the Karoulia et al. Page 31 Cancer Cell. Author manuscript; available in PMC 2017 September 12.
